# Medicinal Chemistry of Benzodiazepine Sedative-Hypnotics
**PHA 548 â€“ Hampton University**  
**Reference:** Foyeâ€™s Principles of Medicinal Chemistry, 8th Ed.

---

## Mechanism of Action â€” GABAA Allosteric Modulation

BZDs bind at **Î±-Î³ interface** of GABAA â†’ â†‘ **frequency** of channel openings.  
Require **endogenous GABA** â†’ overdose safety advantage vs barbiturates.

![BZD binding site](figures/BZ_Allosteric_Binding.jpg)

---

## Required Pharmacophore

Three essential structural elements:

- **C7 electronegative substituent**
- **N1-C2 carbonyl**
- **C5 phenyl (Ring C)**

![Backbone and examples](figures/figure_12.6.jpg)

---

## Structureâ€“Activity Relationships (SAR)

| Modification | Consequence |
|-------------|-------------|
| Remove C7-Cl | â†“ potency / â†“ affinity |
| Add C3-OH | Faster clearance via conjugation |
| Add bulky group para-C5 | Inactive (steric hindrance) |
| Triazolo/imidazo fusion | Protects oxidative soft spots |
| Ester appendage | Ultra-short, soft-drug behavior |

> Medicinal chemistry controls: potency, selectivity, duration, toxicity.

---

## PK-Driven SAR Examples

### Flurazepam & Quazepam  
Long-acting **active metabolites** â†’ residual sedation

![Metabolism](figures/figure_12.7.jpg)

---

### Temazepam  
**Phase II** route â†’ rapid offset

![Glucuronidation](figures/unnumbered_figure_12.6.jpg)

---

### Triazolobenzodiazepines  
Block oxidation with **fused ring**

![Triazolo fusion](figures/figure_12.19.jpg)

---

## Comparative PK Table

![Table 12.2](figures/table_12.2.jpg)

| Drug | Major Metabolic Route | Approx. Outcome |
|------|----------------------|----------------|
| Flurazepam | CYP N-dealkylation | Very long-acting |
| Quazepam | CYP oxidation | Accumulation |
| Estazolam | CYP3A4 | Moderate duration |
| Triazolam | Oxidation â†’ conjugation | Short-acting |
| Temazepam | Glucuronidation | Rapid clearance |
| Remimazolam | Ester hydrolysis | Ultra-short |

---

## Remimazolam â€” Soft-Drug Strategy

![Remimazolam](figures/Remimazolam-metabolism.jpg)

- Ester easily hydrolyzed â†’ non-BZD inactive metabolite  
- Precise sedation onset/offset  
- Minimal hepatic metabolism

---

## Practice â€” Predicting Effects

Given a structure, predict:
1) **Binding** change  
2) **Duration** change  

*Explain in SAR terms.*

---

### Key Concept Summary

| Design Feature | Clinical Effect |
|---------------|----------------|
| â†‘ Lipophilicity | â†‘ CNS entry & duration |
| N-alkyl chains | Long-acting metabolite formation |
| C3-OH | Rapid conjugation & clearance |
| Fused rings | Metabolism protection â†’ shorter |
| Soft-drug ester | Fast turnover â†’ procedural control |

---

ðŸ“Œ End of Lecture Notes
